More about Poly Medicure Limited
Fundamentals for Poly Medicure Limited
Regulatory Filings for Poly Medicure Limited
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
Fundamentals for Poly Medicure Limited
Business Operations:
Sector: HealthcareIndustry: Medical Instruments & Supplies
Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal and tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. It offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. The company provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, ESR pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, universal caps, and ECG electrodes. The company was incorporated in 1995 and is based in New Delhi, India.
Revenue projections:
With POLYMED's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 27.338678 |
| debtToEquity | 8.169000 |
| earningsGrowth | -0.176000 |
| revenueGrowth | 0.164000 |
| grossMargins | 0.679960 |
| operatingMargins | 0.166970 |
| trailingEps | 31.820000 |
| forwardEps | 48.660000 |
POLYMED's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
POLYMED's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.
Poly Medicure Limited's negative gross and operating margins indicate that the company is operating at a loss. This reflects an inability to cover production costs and operational expenses, which could undermine its financial stability.
With a forward EPS greater than its trailing EPS, POLYMED is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.
Price projections:
Over time, Poly Medicure Limited's price projections have been gradually lowered, signaling declining confidence in the company's future outlook. The downward revisions suggest analysts are becoming more cautious about Poly Medicure Limited's potential for growth.
Recommendation changes over time:
The analysts' mixed ratings for POLYMED indicate no clear guidance on whether to buy or sell. Investors may need to explore other data points or wait for more concrete market signals before taking any decisive action regarding POLYMED.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
How Independent Directors Failed Rs 2,500 Crore in Value
India’s Stock Market May Be Sitting on a Trap